CNS PHARMACEUTICALS INC (CNSP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.73-2.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CNSP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CNSP — officer change
Dated 2026-05-04
Director — Jerzy (George) Gumulka: Mr. Gumulka resigned as a member of the Board, and Ms. Fisher was appointed as an independent director.
Why it matters: Buying assets will help the company with its new plans in oncology and neurology.
Supportive ifAt least one completed asset purchase with clear value soon.
Worry ifNo asset acquisitions announced by the end of Q4 2026.
Why it matters: Funding is important for CNS Pharmaceuticals. It helps them keep running and grow.
Supportive ifThey announced a private placement. It raised over $5 million.
Worry ifNo funding secured by the next earnings date on August 13, 2026.
Why it matters: The recent private placement can impact the company's financial health and investor perception. Clarity on its use is key.
Watch forA detailed plan on how the funds from the private placement will be used.
Also watch forNo clear communication on the use of funds or negative market reaction.
Why it matters: If the company buys successful assets, it shows progress in its new plan. This may help growth in oncology or neurology.
Supportive ifThe company says it has finished buying clinical-stage assets. These assets have clear paths for development.
Worry ifIf no acquisitions happen in the next six months, it shows delays in the new plan.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$301 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $902 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,985 loss on $10,000 · 79.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Out-licensing old programs could create value and give funding without diluting shares. This shows good management of current assets.
Supportive ifAnnouncement of at least one out-licensing deal for a legacy program within the next six months.
Worry ifNo progress on out-licensing efforts reported by the end of the year.
Why it matters: This funding is crucial for executing the new strategy. Its effective use could enhance the company's growth potential.
Supportive ifThere are positive updates on how the financing is used. It helps acquire new assets or fund development.
Worry ifReports of continued operating losses without clear plans for the use of the new capital.
Why it matters: Getting more funding is important for the new corporate strategy. This will help with buying and developing assets.
Supportive ifAnnouncement of a new funding round or partnership that adds at least $10 million.
Worry ifIf they do not get more funding in six months, it could be a problem.
Why it matters: The earnings report on August 13 will show if the new strategy is gaining traction. It will be a key indicator of progress.
Watch forThe earnings report shows better financial numbers or good news on strategic plans.
Also watch forThe earnings report shows ongoing losses with no clear plans to improve.
Why it matters: More funding could help carry out the new strategy and asset acquisitions.
Supportive ifThey will announce a new funding round or partnership for asset acquisitions.
Worry ifNo new funding news or partnerships in the next six months show financial limits.
Why it matters: Good management changes can help the company. They can also boost investor trust.
Watch forThey announced a new executive hire that adds strength to the leadership team.
Also watch forThere are more executive departures. This may cause problems in management.
Why it matters: Good management changes are key for the new plan. New leaders can help the company grow.
Watch forThey share good news about new leaders who will help with the strategy.
Also watch forBad news or high turnover in the new leadership team shows problems.
Why it matters: Success in acquiring new assets will show if the company can pivot effectively. This is key for future growth.
Supportive ifLook for news about a new asset purchase in oncology or neurology.
Worry ifNo new asset acquisitions announced within the next six months.
Why it matters: Licensing old programs can bring in money and support the new plan.
Supportive ifLook for news about a signed deal to license an old program.
Worry ifNo news on licensing old programs in the next quarter.
Why it matters: How the company uses this funding will indicate its commitment to the new strategy and growth.
Watch forLook for good news on asset purchases or improvements from the funding.
Also watch forContinued operating losses without clear use of the new funds.